Long-term Evaluation of the Efficacy and Safety of Splentis for the Treatment of Primary Apical Pelvic Organ Prolapse

NCT ID: NCT05042453

Last Updated: 2024-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

140 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-19

Study Completion Date

2030-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective, multi center cohort trial aims to evaluate the efficacy and safety of hysteropexy using Splentis via the vaginal route in primary uterine prolapse

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Women who undergo hysteropexy with Splentis via the vaginal route for primary uterine prolapse will be evaluated regarding efficacy and safety in a long term follow-up of 60 months. The primary endpoint is composed of anatomical, subjective and re-treatment components, whereas several secondary endpoints focusing on functional outcome including overactive bladder symptoms, urinary incontinence, quality of life and sexual life will be considered. Furthermore, a detailed report about adverse events will be included.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pelvic Organ Prolapse

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hysteropexy using Splentis via vaginal route

Non-fertile women ≥ 18 years with uterine descent (POP-Q ≥ 2) which are study-independently scheduled for hysteropexy with Splentis

Splentis® POP Tissue Anchoring System

Intervention Type DEVICE

Anterior cervicopexy with bilateral sacrospinous ligament fixation using Splentis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Splentis® POP Tissue Anchoring System

Anterior cervicopexy with bilateral sacrospinous ligament fixation using Splentis

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* non-fertile women
* primary symptomatic uterine descent POP-Q≥2
* Scheduled apical POP repair with Splentis
* Willing and able to participate at study visits and to sign informed consent

Exclusion Criteria

* Fertile women
* Recurrent apical prolapse
* Women with post hysterectomy vaginal vault prolapse
* Patients with active or latent infection of the vagina, cervix or uterus
* Patients with previous or current vaginal, cervical or uterine cancer
* Previous, current or planned pelvic radiation therapy
* Known allergy to polypropylene.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Promedon

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gert Naumann, MD

Role: PRINCIPAL_INVESTIGATOR

Helios Clinic Erfurt, Germany

Christian Fünfgeld, MD

Role: PRINCIPAL_INVESTIGATOR

Clinic Tettnang

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

DRK Hospital Chemnitz-Rabenstein

Chemnitz, , Germany

Site Status RECRUITING

Helios Hospital Erfurt, Department of gynaecology

Erfurt, , Germany

Site Status RECRUITING

University Hospital Freiburg

Freiburg im Breisgau, , Germany

Site Status RECRUITING

Clinic Kassel

Kassel, , Germany

Site Status RECRUITING

St. Elisabeth Hospital

Leipzig, , Germany

Site Status RECRUITING

University Hospital

Mannheim, , Germany

Site Status NOT_YET_RECRUITING

Hospital Tettnang

Tettnang, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Philipp Schelhorn

Role: CONTACT

00498031900400

Lorena López, Ph.D, Bioeng

Role: CONTACT

005493514596072

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Torsten Brosche, Dr. med.

Role: primary

Gert Naumann, PD Dr.habil.

Role: primary

Markus Hübner, Prof. Dr. med.

Role: primary

Christiane Schiffner, Dr. med.

Role: primary

Birgit Henne, Dr. med.

Role: primary

Benjamin Tuschy, Prof. Dr. med.

Role: primary

Christian Fünfgeld, Dr.med.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Sax_Pro

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.